Norges Bank bought a new stake in Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 20,000 shares of the company's stock, valued at approximately $348,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pulse Biosciences during the 3rd quarter valued at $588,000. Charles Schwab Investment Management Inc. grew its position in shares of Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock valued at $2,598,000 after purchasing an additional 97,565 shares in the last quarter. State Street Corp raised its stake in shares of Pulse Biosciences by 17.8% during the 3rd quarter. State Street Corp now owns 461,333 shares of the company's stock valued at $8,092,000 after purchasing an additional 69,696 shares during the period. Geode Capital Management LLC boosted its stake in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock worth $8,020,000 after purchasing an additional 33,200 shares during the period. Finally, Franklin Resources Inc. purchased a new position in Pulse Biosciences during the 3rd quarter valued at about $378,000. Institutional investors own 76.95% of the company's stock.
Analyst Ratings Changes
Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.
View Our Latest Report on PLSE
Pulse Biosciences Trading Down 0.1 %
Shares of PLSE stock traded down $0.01 on Thursday, reaching $16.88. The company's stock had a trading volume of 19,477 shares, compared to its average volume of 196,476. Pulse Biosciences, Inc. has a 12-month low of $6.60 and a 12-month high of $25.00. The stock's 50 day simple moving average is $17.49 and its 200-day simple moving average is $17.91.
Pulse Biosciences Profile
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
